The evolving role of aromatase inhibitors in adjuvant breast cancer therapy

Clinical Breast Cancer

Volumn 6, Issue 3, 2005, Pages 206-215

  Henderson, I Craig ^a   Piccart Gebhart, Martine J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

Anastrozole; Clinical trials; Exemestane; Letrozole; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN; EXEMESTANE; LETROZOLE; MEGESTROL ACETATE; PLACEBO; TAMOXIFEN; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADJUVANT THERAPY; ARTHRALGIA; ARTHRITIS; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FOLLOW UP; HORMONAL THERAPY; HOT FLUSH; HUMAN; LONG TERM CARE; METASTASIS; MONOTHERAPY; MYALGIA; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOEMBOLISM; VAGINA BLEEDING; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CASE REPORT; DRUG COMBINATION; FEMALE; MIDDLE AGED; PAGET NIPPLE DISEASE;

ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN;

EID: 32944460981     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2005.n.022     Document Type: Review

References (53)

1. Winer WC, Morrow M, Osborne CK. Malignant tumors of the breast. In DeVita VT, Hellman S, Rosenberg SA, et al, eds. Cancer. Principles and Practice of Oncology, 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:1651-1726.
2. Willett WC, Rockhill B, Hankinson SE, et al. Epidemiology and non-genetic causes of breast cancer. In: Harris JR, Lippman ME, Morrow M, et al, eds. Diseases of the Breast, 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:175-220.
3. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339:1609-1618.
4. Early Breast Cancer Trialists' Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351:1451-1467.
5. Jordan VC, Costa, AF. Chemoprevention. In: Harris JR, Lippman ME, Morrow M, et al, eds. Diseases of the Breast, 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:265-279.
6. Katzenellenbogen BS, Frasor J. Therapeutic targeting in the estrogen receptor hormonal pathway. Semin Oncol 2004; 31(suppl 3):28-38.
7. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004; 96:926-935.
8. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348:2431-2442.
9. Campos SM. Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist 2004; 9:126-136.
10. Baum M, Buzdar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. ATAC Trialists' Group [published erratum in Lancet 2002; 360:1520]. Lancet 2002; 359:2131-2139.
11. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349:1793-1802.
12. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. Intergroup Exemastane Study [published erratum in N Engl J Med 2004; 351:2461]. N Engl J Med 2004; 350:1081-1092.
13. Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996; 88:1543-1549.
14. Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group. Preliminary results from the Cancer Research Campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst 1996; 88:1834-1839.
15. Stewart HJ, Forrest AP, Everington D, et al. Randomised comparison of 5 years adjuvant tamoxifen with continuous therapy for operable breast cancer. the Scottish Cancer Trials Breast Group. Br J Cancer 1996; 74:297-299.
16. Tormey D, Gray R, Falkson H. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group. J Natl Cancer Inst 1996; 88:1828-1833.
17. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996; 88:1529-1542.
18. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001; 93:684-690.
19. National Cancer Research Network Trials Portfolio. NCRN web site. Available at: http://www.ncrn.org.uk/portfolio/data.asp. Accessed July 6, 2004.
20. Fisher B, Constantino JR Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998; 90:1371-1388.
21. Day R, Ganz PA, Constantino JP, et al. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast Bowel Project P-1 study. J Clin Oncol 1999; 17:2659-2669.
22. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer [published erratum in J Natl Cancer Inst 2000; 92:275]. J Natl Cancer Inst 1999; 91:1829-1846.
23. Osborne CK, Jarman M, McCague R, et al. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 1994; 34:89-95.
24. Liu H, Lee ES, Gajdos C, et al. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst 2003; 95:1586-1597.
25. Come SE, Buzdar AU, Arteaga CL, et al. Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clin Cancer Res 2004; 10(1 pt 2):327s-330s.
26. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1993; 24:85-95.
27. Carlomagno C, Perrone F, Gallo C, et al. C-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996; 14:2702-2708.
28. Yamauchi H, O'Neill A, Gelman R, et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997; 15:2518-2525.
29. Lipton A, Ali SM, Leitzel K, et al. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. Proc Am Soc Clin Oncol 2000; 19:71a (Abstract #274).
30. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001; 19:2334-2356.
31. De Placido S, De Laurentiis M, Carlomagno C, et al. Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 2003; 9:1039-1046.
32. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19:3808-3816.
33. Smith I, Dowsett M. Comparison of anastrozole vs. tamoxifen alone in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. San Antonio Breast Cancer Symposium 2003; (Abstract #1).
34. Dowsett M, Smith IE, for the IMPACT trialists. Molecular effects of anastrozole (A) and tamoxifen (T) alone and combined (C) in the IMPACT trial of neoadjuvant treatment of primary breast cancer. Proc Am Soc Clin Oncol 2004; 23:11 (Abstract #537).
35. Lonning PE. Aromatase inhibitors in breast cancer. Endocr Relat Cancer 2004; 11:179-189.
36. Miller WR. Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treat Rev 1989; 16:83-93.
37. Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromastase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996;74:1286-1291.
38. Geisler J, Haynes B, Anker G, et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, crossover study. J Clin Oncol 2002; 20:751-757.
39. Dowsett M, Jones A, Johnston SR, et al. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1995; 1:1511-1515.
40. Geisler J, King N, Anker G, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998; 4:2089-2093.
41. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18:3748-3757.
42. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 2000; 18:3758-3767.
43. Dirix L, Piccart MJ, Lohrish C, et al. Efficacy and tolerance to exemestane (E) versus tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): a European Organisation for the Research and Treatment of Cancer (EORTC Breast Group) phase II trial with Pharmacia and Upjohn. Proc Am Soc Clin Oncol 2001; 20:29a (Abstract #114).
44. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group [published erratum in J Clin Oncol 2001; 19:3302]. J Clin Oncol 2001; 19:2596-2606.
45. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92:2247-2258.
46. Paridaens R, Therasse L, Dirix L, et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts): a randomized phase III trial of the EORTC Breast Group. Proc Am Soc Clin Oncol 2004; 23:6 (Abstract #515).
47. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. ATAC Clinical Trialists' Group. Cancer 2003; 98:1802-1810.
48. Dowsett M, on behalf of the ATAC Clinical Trialists' Group. Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 2003; (Abstract #4).
49. Howell A, on behalf of the ATAC Trialists Group. ATAC ('Arimidex', tamoxifen, alone or in combination) completed treatment analysis: anastrozole demonstrates superior efficacy and tolerability compared with tamoxifen. San Antonio Breast Cancer Symposium 2004; (Abstract #1).
50. Goss PE, Ingle JN, Martino S, et al. Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women wity early stage breast cancer. Proc Am Soc Clin Oncol 2004; 22: 14S (Abstract #847).
51. Thurlimann B, for the BIG 1-98 Collaborative Group. Letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Presented at the 9th International Conference on Primary Therapy of Early Breast Cance;, January 26, 2005. Available at: www.ibcsg.org/BIG 1-98 press kit/presentation. Accessed March 4, 2005.
52. Jakesz R, Kaufmann M, Gnant M, et al, on behalf of the ABCSG, the GABG. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3,123 women enrolled in the ABCSG trial 8 and the ARNO 95 trial. Presented at the San Antonio Breast Cancer Symposium, December 2004. Available at: www.sabcs.org/symposiumonline/index.asp. Accessed March 4, 2005.
53. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996; 14:2738-2746.